MBC-11 triethylamine
MBC-11 triethylamine is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 triethylamine has the potential for tumor-induced bone disease (TIBD) research.
For research use only. We do not sell to patients.
- Formula: C17H35N4O14P3
- Molecular Weight:612.40
-
Storage:
-20°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
MBC-11 shows similar activity profiles and significantly inhibits growth of all three cell lines between 10-8 and 10-4 M. MBC-11 decreases KAS-6/1 cell growth from approximately 56% at 10-8 M to 6% at 10-5 M[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human multiple myeloma cell lines (KAS-6/1, DP-6, KP-6).
-
Concentration:Between 10-8 and 10-4 M
-
Incubation Time:48 hours.
-
Result:Significantly inhibited multiple myeloma cell proliferation of each cell line at the majority of the tested concentrations.
Weight gained in mice treated with up to 500 μg/day of MBC-11 is similar to the PBS treated group[1].
These results demonstrate that MBC-11 decreases bone tumor burden, maintains bone structure, and may increase overall survival, warranting further investigation as a treatment for tumor-induced bone disease (TIBD)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Approximately four-week old female Balb/c mice inoculated (s.c. injection into their mammary fatpads) with 500,000 4T1/luc cells at day 0 (breast tumor model)[1].
-
Dosage:0.04, 0.4, or 4.0 μg/day.
-
Administration:S.C. daily from day 7 to 21.
-
Result:47% of 17 mice treated with MBC-11 had detectable bone metastases. The dose of 0.04 μg/day had a lower incidence of bone metastases compared to those treated with PBS or 0.04 μg/day zoledronate.
-
Animal Model:Female Balb/c and SCID mice (four-six weeks old)[1].
-
Dosage:500, 100, 1, or 0.01 μg/100 μL.
-
Administration:S.C. daily for 24 or 49 days.
-
Result:Weight gained in MBC-11 treated mice with different doses was similar to the PBS treated group.
Chemical Information
-
Appearance Solid
-
Molecular Weight 612.40
-
Formula C17H35N4O14P3
-
Color White to off-white
-
SMILES
CCN(CC)CC.CC(P(O)(O)=O)(P(O)(OP(O)(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C=CC(N)=NC2=O)O1)=O)=O)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Reinholz MM, et al. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul;47(1):12-22. [Content Brief]
[2]. Zinnen SP, et al. First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease. Oncologist. 2019 Mar;24(3):303-e102. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MBC-11 triethylamine Related Classifications
HY-107093B Related Classifications
Powered by Bioz